New Fasenra data from the MELTEMI extension trial confirm long-term safety and efficacy in severe eosinophilic asthma for up to five years
PharmiWeb,
Data confirm Fasenra’s well-established safety profile consistent with previous Phase III trials At least 75% of Fasenra-treated…
